SAN DIEGO, April 18 /PRNewswire-FirstCall/ -- Nanogen, Inc. , developer of advanced diagnostic products, announced today that it has entered into a supply and license agreement with deCode Genetics to provide a new genomics assay for single nucleotide polymorphism (SNP) discovery, validation and screening. The assay incorporates a full range of Nanogen's products, including the Eclipse(R) Dark Quencher, new DNA linker technology, modified bases and novel fluorescent dyes, and allows rapid SNP analysis on a large number of patient samples.
"The products and assay that we will provide deCode represent our comprehensive product menu available from the recent merger of Nanogen and Epoch Biosciences," said Howard C. Birndorf, Nanogen's chairman of the board and CEO. "We are pleased deCode has joined our roster of licensing partners eager to tap our growing portfolio of products that enable rapid, high-throughput genetic analysis."
About Nanogen, Inc.
Nanogen's advanced diagnostics provide physicians and patients worldwide with sophisticated information to predict, diagnose and treat disease. Research and clinical reference labs use the highly accurate and reliable NanoChip(R) Molecular Biology Workstation, NanoChip(R) Electronic Microarray and broad suite of analyte specific reagents to develop diagnostic tests for variety of diseases. Nanogen also offers a broad portfolio of patented nucleic acids chemistries and molecular tools that accelerate genomic analysis and are compatible with many systems. The SynX subsidiary offers a line of point-of-care diagnostic tests and is building expertise in cardiac related health conditions. Nanogen's ten years of pioneering research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. For additional information please visit Nanogen's website at http://www.nanogen.com/.
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
CONTACT: Robert Saltmarsh, VP Corporate Development of Nanogen, Inc.,+1-858-410-4600, email@example.com; or Pam Lord, Media & InvestorRelations, +1-858-527-3494, firstname.lastname@example.org, for Nanogen, Inc.